Page 224 - Drug Class Review
P. 224
Page 142 of 205
Drug Effectiveness Review Project
placebo 72% 11.9% Significant differences favoring placebo: confusion 7.9% vs. 2% (P = 0.01); headache 6.4% vs. 2.5% (P = 0.09); significant differences favoring MEM: diarrhea 4.5% vs. 8.5% (P = NR) and fecal incontinence placebo 25.4% 12.4%
memantine 78% 9.4% Post randomization exclusions: NR Overall loss to follow-up: 20% Loss to follow-up differential high: Yes memantine 14.9% 7.4%
2% vs. 5% (P = NR) ITT: Yes Yes Yes NR Fair
Final Report Update 1 Authors: Tariot et al. Year: 2004 ADVERSE EVENTS: Overall adverse effects reported: Agitation • Significant differences in adverse events: ANALYSIS: ADEQUATE RANDOMIZATION: ADEQUATE ALLOCATION CONCEALMENT: BLINDING OF OUTCOME ASSESSORS: ATTRITION (overall): ATTRITION (treatment specific): Loss to follow-up: Withdrawals due to adverse events: QUALITY RATING: *primary outcome measures Alzheimer's Drugs
